Last reviewed · How we verify
PC14586
At a glance
| Generic name | PC14586 |
|---|---|
| Also known as | rezatapopt |
| Sponsor | PMV Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PHASE1, PHASE2)
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants (PHASE1)
- A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants (PHASE1)
- Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers (PHASE1)
- AME Study of [14C]-PC14586 in Healthy Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PC14586 CI brief — competitive landscape report
- PC14586 updates RSS · CI watch RSS
- PMV Pharmaceuticals, Inc portfolio CI